Related Experiment Video
Updated: Jul 2, 2026

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
Published on: October 26, 2020
Current Options for Kidney Protection: Are Renin-Angiotensin System Inhibitors Still Relevant?
1Boston, Massachusetts.
Abstract:
Chronic kidney disease progresses through convergent mechanisms involving hemodynamic stress, proteinuria, inflammation, fibrosis, and metabolic disturbance. Barry Brenner's hyperfiltration hypothesis established these processes as drivers of ongoing injury, and landmark trials established that renin-angiotensin-aldosterone system (RAAS) inhibition slows progression and improves clinical outcomes, marking a shift from supportive care to disease-modifying treatment. Treatment options have since expanded, with newer therapeutic classes providing additional kidney and cardiovascular benefit alongside emerging agents with more targeted mechanisms of action. Approaches to prognostic assessment have also advanced through biomarkers, genetics, imaging, and digital tools, although integration into clinical practice remains incomplete. More than 4 decades after their introduction, RAAS inhibitors remain a core component of kidney protection, with newer therapies complementing rather than replacing them.
Insights
Renin-angiotensin-aldosterone system (RAAS) inhibition remains crucial for slowing chronic kidney disease progression. Newer therapies complement RAAS inhibitors, offering enhanced kidney and cardiovascular benefits.
Area of Science:
- Nephrology
- Cardiovascular Medicine
- Pharmacology
Background:
- Chronic kidney disease (CKD) involves complex mechanisms like hemodynamic stress, proteinuria, inflammation, fibrosis, and metabolic issues.
- Barry Brenner's hyperfiltration hypothesis identified these as key drivers of kidney injury.
- Renin-angiotensin-aldosterone system (RAAS) inhibition revolutionized CKD treatment by slowing progression and improving outcomes.
Purpose of the Study:
- To review the evolution of CKD treatment strategies.
- To highlight the enduring role of RAAS inhibitors and the emergence of new therapeutic classes.
- To discuss advancements in CKD prognostic assessment.
Main Methods:
- Literature review of landmark trials and therapeutic advancements in CKD.
- Analysis of the role of RAAS inhibition in kidney protection.
- Examination of novel therapeutic agents and prognostic tools.
Main Results:
- RAAS inhibitors are a cornerstone of CKD management, significantly slowing disease progression.
- Newer therapeutic classes offer additional kidney and cardiovascular benefits.
- Prognostic assessment has advanced with biomarkers, genetics, imaging, and digital tools, but clinical integration is ongoing.
Conclusions:
- RAAS inhibitors remain essential for kidney protection in CKD.
- Emerging therapies complement, rather than replace, established RAAS inhibitor treatments.
- Integrated prognostic tools are needed for comprehensive CKD management.
Related Concept Videos
Antihypertensive Drugs: Direct Renin Inhibitors
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Acute Kidney Injury V: Interprofessional Care
Chronic Kidney Disease III: Interprofessional Care
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
